A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation.

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Abstract Text:

P J Boyne,R E Marx,M Nevins,G Triplett,E Lazaro,L C Lilly,M Alder,P Nummikoski,

This 16-week open-label study assessed the safety and technical feasibility of implanting human recombinant bone morphogenetic protein-2 delivered on an absorbable collagen sponge (rhBMP-2/ACS) for two-stage maxillary floor sinus augmentation. This first use of rhBMP-2/ACS in human clinical maxillary sinus floor augmentation included 12 patients with inadequate bone height in the posterior maxilla. The total delivered dose of rhBMP-2 implanted varied from 1.77 to 3.40 mg per patient. The rhBMP-2/ACS device was easily handled. Significant bone growth was documented by computerized tomographic scans in all evaluable patients (11/12). The overall mean height response for the maxillary sinus floor augmentation was 8.51 mm (95% confidence interval 6.07 to 10.95). There were no serious or unexpected immunologic or adverse effects and no clinically significant changes in complete blood counts, blood chemistries, or urinalysis results. The most frequent adverse effects were facial edema, oral erythema, pain, and rhinitis. Eleven patients have received dental implants and follow-up examinations are still being conducted. Histologic examinations of core bone biopsies obtained at the time of dental implant placement confirmed the quality of the bone induced by rhBMP-2/ACS. These results tend to indicate that rhBMP-2/ACS may provide an acceptable alternative to traditional bone grafts and bone substitutes for maxillary sinus floor augmentation procedures in humans.

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Publishing Authors By Initials

PJ Boyne,RE Marx,M Nevins,G Triplett,E Lazaro,LC Lilly,M Alder,P Nummikoski,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The International journal of periodontics & restor

VOLUME: 17

Page Numbers: 11-25

Journal Abbreviation:

ISSN: 0198-7569

DAY: 19

MONTH: Feb

YEAR: 1997

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8200894

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: pharmacology

Chemical & Substance for Abstract: A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Information

Substance Name: Collagen

Registry Number: 9007-34-5

Grant and Affiliation Information for A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation.

AFFILIATION: Department of Oral and Maxillofacial Surgery, School of Dentistry, Loma Linda University, California, USA.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Periodontics Restorative

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation Related Publications

• A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation.